Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Danaher, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Danaher is expected to report quarterly earnings of $1.62 per share, reflecting a year-over-year decrease of 15.6% [3]. - Revenue projections stand at $5.56 billion, down 4.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.07% over the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP of +0.33% suggests analysts have recently become more optimistic about Danaher's earnings prospects [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Danaher currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Danaher was expected to post earnings of $2.17 per share but delivered $2.14, resulting in a surprise of -1.38% [12]. - Over the past four quarters, Danaher has beaten consensus EPS estimates three times [13]. Conclusion - While Danaher is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [16].

4月1日，碧迪拟出售生命科学业务事件有了最新进展，该公司正与科学仪器行业两大巨头 赛默飞、丹纳赫 就出售其生命科学业务进行谈判。 此外，该公司还在与 沃特世、凯杰、瑞孚迪 等体量较小的潜在买家探索通过"反向莫里斯信托"免税换股方式完成交易。 早在2月6日，碧迪向外界披露了其正有条不紊地筹备拆分旗下极具价值的生命科学部门。该部门包括集成诊断解决方案（IDS）部门和生物科 学业务（BDB）部门。其中，IDS业务将保留在新的碧迪集团内。 导读： 4月1日，碧迪拟出售生命科学业务事件有了最新进展，该公司正与科学仪器行业两大巨头赛默飞、丹纳赫、沃特世、凯杰、瑞孚迪等就出售其生命科学业 务进行谈判。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 谁将成为最后赢家？ 如今，赛默飞、丹纳赫、沃特世、凯杰、瑞孚迪5潜在买家率先浮出水面，不意外的，都是科学仪器行业"知名老演员"。那么，谁将成为最后赢 家？ 据悉，此次拆分是由激进投资者St a r b o a r d Va l u e推动的。他们坚信，拆分后的生命科学部门能够摆脱原有的组织架构束缚，以更加独立 ...

Core Business Performance - Danaher Corporation (DHR) is experiencing strong momentum in its clinical diagnostics business, particularly from the Leica Biosystems and Beckman Colter Diagnostics units, with positive responses to new products like Aperio GT 450 DX and Access NT ProBNP, both of which received FDA 510K clearance [1] - The Diagnostics segment's core revenues increased by 3% year over year in 2024, with expectations for 2025 to remain flat or increase in low-single-digits [2] - The acquisition of Abcam plc for approximately $5.7 billion in December 2023 has expanded Danaher's Life Sciences segment, contributing to a 2% revenue boost in 2024 [3] Shareholder Returns - Danaher is committed to rewarding shareholders, having paid out dividends of $768 million in 2024 and $821 million in 2023, with an 18.5% dividend hike to 32 cents per share announced in February 2025 [4] Segment Challenges - The Life Sciences segment faced a 2% decline in core revenues year over year in 2024 due to sluggish demand in pharma and biotech markets in China, impacting sales in mass spectrometry, flow cytometry, lab automation, and microscopy [5] - The Biotechnology segment also showed weakness, with core revenues declining by 4.5% year over year in 2024 due to sluggish demand in discovery and medical businesses [6] Financial Concerns - Danaher reported a long-term debt of $15.5 billion at the end of Q4 2024, with current liabilities of $6.8 billion exceeding cash equivalents of $2.1 billion, and high interest expenses of $278 million in 2024 [7] Stock Performance - Over the past year, Danaher's stock has declined by 19%, compared to a 16% decrease in the industry [8]

Group 1 - The article promotes a research service focused on various income-generating investment vehicles such as REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs, highlighting its comprehensive nature and positive user testimonials [1] - It mentions that there are 438 testimonials, with most being rated 5 stars, indicating high customer satisfaction and trust in the service [1] Group 2 - The article includes a disclosure from the analyst stating a beneficial long position in DHR shares, which may influence the analysis presented [2] - It clarifies that the opinions expressed are those of the author and not influenced by any compensation from companies mentioned, ensuring transparency in the analysis [2] Group 3 - The article emphasizes that past performance does not guarantee future results, which is a standard disclaimer in investment analysis [3] - It notes that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a diversity of opinions among contributors [3]

Company Overview - Danaher Corporation (NYSE: DHR) is a global company recognized for integrating science and technology [1] - The company operates through three reportable segments: Diagnostics, Life Sciences, and Biotechnology [1] - Danaher has a market capitalization of approximately $150 billion and employs over 60,000 people worldwide [1]

I have over 15 years of experience investing and have provided research services to mid-sized hedge funds with assets under management between $100 and $500 million. I also have had a brief stint as a sell-side analyst. I am now focusing primarily on managing my own money and my purpose here is to share my views and benefit from the insights of the Seeking Alpha user community. Feel free to provide your feedback on my thesis in the comment section and I would love to have a discussion even if you have a var ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年3月24日，为期三天的 第二十二届中国国际检验医学暨输血仪器试剂博览会（CACLP） 在杭州大会展中心正式落下帷幕。 此次大会，迈瑞医疗发布了 MT 8000S独立式智能样本处理系统 ，覆盖从样本签收到上机检测前的所有处理环节，通过数字视觉和模型算法，确保整个样本处理 过程处于IT+AI控制之下。另外，迈瑞还发布了 全新一代H-120全自动糖化血红蛋白分析仪、CX—9000高端凝血分析仪和MN 2880全自动核酸提纯及实时荧光 PCR分析系统 （分子诊断领域的重要产品，定义核酸检测新常规）。 作为全球体外诊断（IVD）行业极具影响力的盛会之一，本届展会以" 以创新的力量，助力IVD产业健康发展 "为主题，全方位展示了体外诊断领域的最新技术和产 品。随着人工智能、大数据、物联网等技术的迅猛发展，智能化诊断成为本届展会的最大亮点。 此次大会， 丹纳赫、罗氏、雅培、豪洛捷等 国际巨头携最新研发成果强势登场，全方位覆盖仪器、试剂、原材料等关键展区。从前 ...

Group 1 - The article highlights that it is a favorable time for growth investors as valuations of previously high-flying stocks have decreased significantly [2] - Danaher Corporation (NYSE: DHR) is mentioned as a potential investment opportunity, currently priced at $210 [2] Group 2 - The content emphasizes the importance of conducting due diligence and making independent investment decisions [3][4]

Core Viewpoint - Danaher Corporation will host a quarterly earnings conference call for Q1 2025 on April 22, 2025, at 8:00 a.m. ET to discuss financial performance and future expectations [1]. Group 1: Earnings Call Details - The earnings call will be available via webcast on Danaher's website under the "Investors" section [2]. - A replay of the webcast will be accessible shortly after the call and will remain available until the next quarterly earnings call [2]. - Participants can access the conference call by dialing specific numbers for U.S. and international callers, with a Conference ID provided [3]. Group 2: Company Overview - Danaher is a global leader in life sciences and diagnostics, focusing on improving human health through science and technology [4]. - The company collaborates with customers to address significant health challenges, enabling faster and more accurate diagnoses [4]. - Danaher employs approximately 63,000 associates worldwide, dedicated to enhancing quality of life and fostering a sustainable future [4].

Core Insights - The new DxC 500i Clinical Analyzer from Beckman Coulter Diagnostics has received 510(k) clearance from the U.S. FDA, enhancing laboratory capabilities with advanced technology and user-friendly interface [1][2] - The analyzer can perform up to 800 clinical chemistry tests and 100 immunoassay tests per hour, providing precise results essential for clinical decision-making [1] Company Overview - Beckman Coulter Diagnostics is a leader in clinical diagnostics, focusing on improving patient health through innovative diagnostic solutions for over 90 years [7] - The company is part of Danaher Corporation, leveraging combined capabilities to enhance healthcare through advanced science and technology [8] Product Features - The DxC 500i features FlexMode operations, allowing prioritization of tests based on sample urgency, and includes a dynamic sample handler for optimized throughput [4] - It incorporates technology from the previously launched DxC 500 AU Chemistry Analyzer, ensuring high performance and standardized reagents across healthcare networks [5] Market Context - Approximately 45% of clinical laboratories in the U.S., totaling over 11,000 labs, are part of Integrated Delivery Networks (IDNs), which enhance resource management and quality of care [3] - Innovations like the DxC 500i are designed to meet the needs of networked laboratories, providing strategic benefits in patient care and inventory management [4]